Exabis Library
Welcome to the e-CCO Library!
P471: Predictors of bowel damage in long term progression of Crohn’s disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P471: Real-world experience of using Tofacitinib in Ulcerative Colitis in biologic naïve and biologic exposed patients
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P471: Safety analysis of multimatrix mesalazine amongst patients with ulcerative colitis or recurrent diverticulitis ≥ 55 years of age
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P472 Optimising the development of apps for the management of inflammatory bowel disease and participation in clinical trials
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P472: Changes in colectomy for Ulcerative Colitis during the last two decades: an in-depth retrospective analysis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P472: Cyclosporine versus infliximab in patients with Acute Severe Ulcerative Colitis: A single-centre retrospective study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P472: Efficacy of intravenous ustekinumab re-induction in patients with Crohn’s disease with a loss of response
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P472: Faecal calprotectin as a biomarker of early mucosal healing in patients with ulcerative colitis naïve to adalimumab treatment
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P472: Impact of anti-TNF-alfa therapy on colectomy rates and indications for surgery in Ulcerative Colitis: Comparison of two patient cohorts from 2005 to 2007 and 2014 to 2016
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P472: Original and biosimilar infliximab: Are they two faces of the same coin? The experience from a pioneer European center
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P472: Payer addressable burden of Crohn’s disease in patients treated with ustekinumab and vedolizumab in the United States
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P473 Long-term follow-up of switching from original adalimumab to adalimumab biosimilar: real-world data in IBD
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P473: Clinical and biochemical factors that influence response in inflammatory disease patients receiving tacrolimus
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P473: Contrasting the use of 5-ASA in patients with Ulcerative Colitis and Crohn's Disease: A cross-sectional analysis at a tertiary care IBD clinic
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P473: Corticosteroid-free clinical remission rates with guselkumab maintenance therapy in patients with moderately to severely active Crohn's disease: Week 48 analyses from the phase 2 GALAXI 1 study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P473: Cumulative histological inflammation predicts colorectal neoplasia in ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P473: How to monitor the withdrawal of maintenance treatment with azathioprine in IBD patients with deep remission: results from a prospective study on multiple non invasive tests
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P473: Real world experience with the Crohn's Disease Exclusion Diet (CDED) in a tertiary IBD clinic
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P473: Ustekinumab and vedolizumab influence on cardiovascular risk factors in patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P474 Efficacy and safety of GCAP therapy for UC with PSC
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM